A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Clinical trial NCT02791334 · COMPLETED

Trial details

NCT number: NCT02791334
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Microsatellite Instability-High (MSI-H) Solid Tumors Cutaneous Melanoma Pancreatic Cancer Breast Cancer (HR+HER2-)

Start date: 2016-06-29
Primary completion: 2020-05-22
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.